-
Michael Hayden, Teva's new president of global R&D, plans to integrate generics and branded development, beef up efforts in discovery and personalized medicines, and partner with academics, charities and biotechs.
Published on 5/14/2012
-
A handful of health plans and pharma companies are experimenting with new contracting models that tie reimbursement to health outcomes instead of drug volumes.
Published on 5/14/2012
-
Actelion's agenda after Macitentan's success in make-or-break Phase III for PAH
Published on 5/7/2012
-
Jazz plans to use its revenue-generating track record to woo specialty acquisition candidates with development stage assets.
Published on 5/7/2012
-
While the Epizyme-Celgene deal has similarities to the deal struck by Constellation and Genentech, the pacts are structured differently because the smaller biotechs have different visions for their future.
Published on 4/30/2012
-
While combining BMS's daclatasvir and Gilead's GS-7977 produced a 100% SVR rate in a Phase II study, the two may eschew the opportunity to be first with a pan-genotypic HCV therapy. A split would increase technology …
Published on 4/30/2012
-
A couple of bucks more HGS pipeline Like its marketed lupus treatment Benlysta belimumab, many of the clinical programs at Human Genome Sciences Inc. (NASDAQ:HGSI) are partnered with suitor GlaxoSmithKline plc (LSE:…
Published on 4/23/2012
-
Experienced consultants and adaptive listening have allowed Chiome to crack the code on business development outside of Japan, resulting in three deals in six months.
Published on 4/23/2012
-
Holding out for more money from GSK seems the most likely scenario for Human Genome Sciences, given the small value ascribed to the biotech's assets outside the partnership and the faint hope for a white knight.
Published on 4/23/2012
-
Merck sifted through seemingly conflicting data and concluded vintafolide's PFS benefit in a Phase II trial for platinum-resistant ovarian cancer was robust enough to pay Endocyte $120 million up front for the program.
Published on 4/23/2012
-
Anaphore acquired Shanghai-based RuiYi to provide the company with a GPCR-targeting mAb platform to complement its Atrimer small molecules, and to establish a foothold in China.
Published on 4/16/2012
-
Divvying up skill sets Psoriasis comps Phase II and Phase III data from selected molecules to treat moderate to severe plaque psoriasis show that the 210 mg dose of brodalumab from Amgen Inc. (NASDAQ:AMGN) has the …
Published on 4/9/2012
-
The Amgen-AstraZeneca inflammation deal gives AZ five complementary clinical programs and Amgen the ability to free up resources for other pipeline candidates.
Published on 4/9/2012
-
Shire envisions FerroKin's oral iron chelator as the backbone of a new commercial hematology unit.
Published on 4/2/2012
-
Facing a layoff, ArQule's research team got to work on a cancer stem cell technology that became Boston Biomedical in 2006, which Dainippon now is buying for $200 million.
Published on 3/19/2012
-
Pfizer and Biocon have ended a deal for biosimilar insulins, apparently because the pharma has concluded biosimilar mAbs are higher value.
Published on 3/19/2012
-
Five years after Merck KGaA acquired Serono, for $13.2B, it has grown the top line but finds itself with a high cost structure and thin pipeline. Dealing with the first may buy time to partner for novel assets.
Published on 3/19/2012
-
Remaking Merck Serono Merck Serono comps Compared to eight companies with annual revenues in the neighborhood of the €5.9 billion ($7.7 billion) it reported in 2011, Merck Serono S.A. is near the bottom in terms of …
Published on 3/19/2012
-
Remaking Merck Serono Merck Serono margins The drug business within Merck KGaA (Xetra:MRK) had an operating margin of only 10% in 2005. That improved to the low to mid-20% range with the acquisition of Serono S.A., …
Published on 3/19/2012
-
Remaking Merck Serono Merck Serono deals Since the beginning of 2011, Merck Serono S.A. has done at least eight deals to either in-license or generate candidates in autoimmune, inflammation, cancer and …
Published on 3/19/2012
-
Remaking Merck Serono Serono pipeline attrition Serono S.A. had at least 14 compounds in development in 2006 prior to its acquisition by Merck KGaA (Xetra:MRK). Only three remain, and only two of those have advanced…
Published on 3/19/2012
-
Bristol-Myers Squibb and Duke think their partnership could be a model for other pharmas and universities to help find and accelerate projects across all stages of drug development.
Published on 3/12/2012
-
Japan's drive to catch up with the industrialized world in vaccines is driving deals like Daiichi Sankyo's JV with GSK and Mitsubishi Tanabe's deal to develop vaccines with Medicago's VLP technology.
Published on 3/12/2012
-
Galapagos' big hybrid deal with Abbott was driven by the biotech's desire to control Phase II studies while still locking in an experienced Phase III partner for GLPG0634 in RA and follow-on indications.
Published on 3/5/2012
-
Celladon was unable to partner its heart failure gene therapy after a small initial trial. Instead, the company raised $43 million from the venture arms of several pharmas it had approached about a licensing deal.
Published on 3/5/2012